

Greater Manchester Joint Formulary & RAG/DNP list change log

25 November 2021

The list below includes changes made in the last 12 months. For information on older updates, contact nuth.enquires.gmmmg@nhs.net

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
25/11/2021	2	2.12	Inclisiran added to formulary and RAG list as a GREEN drug, with link to TA733 and note that implementation materials are in development.	Y	Y	7.1
17/11/2021	3	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	7.0
17/11/2021	4	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	9.0
16/11/2021	1	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	7.0
16/11/2021	2	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	7.0
12/11/2021	10	10.1.3	Link to NICE TAs 715, 718 & 719 added to formulary	n/a	Y	7.0
12/11/2021	10	10.1.3	MHRA DSU for tofacitinib (Oct 2021) added to formulary, replacing previous HCP letter.	n/a	Y	7.0
12/11/2021	10	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	7.0
12/11/2021	RAG		Vortioxetine entry on RAG list aligned with formulary	Y	n/a	n/a
05/11/2021	RAG		Link to NHS Choices resource "supplements: who needs them" deleted, resource no longer available.	Y	n/a	n/a
18/10/2021	1	1.5.2	Budesonide orodispersible tablets (Jorveza) assigned GREEN (following specialist initiation) status, and annotated "as per TA708 only for inducing remission of eosinophilic oesophagitis in adults (treatment duration of up to 12 weeks)."	Y	Y	6.3
18/10/2021	2	2.12	Bempeidoic acid assigned GREEN (specialist initiation) RAG status	Y	Y	6.5
18/10/2021	2	2.8.2	Andexanet alfa assigned RED RAG status	Y	Y	6.5
18/10/2021	2	2.8.2	Link to NPSA alert on DOACs and mechanical heart valves added to formulary	n/a	Y	6.5
18/10/2021	4	4.1.1	Melatonin 2mg MR tablets (Circadin) added to formulary as GREEN (following specialist advice) for REM sleep behaviour disorder in Parkinson's disease	Y	Y	8.4
18/10/2021	5	5..3	Remdesivir for COVID-19 added to formulary as a RED drug, in line with NG191	Y	Y	6.2
18/10/2021	6	6.4.1.2	Ulipristal acetate reinstated to formulary as a RED drug, with links to NICE guidance (NG88) and MHRA DSU (Feb 2021)	Y	Y	8.4
18/10/2021	6	6.5.2	Demeclocycline assigned RED RAG status for hyponatraemia associated with SIADH, annotated new patients only from October 2021	Y	Y	8.4
18/10/2021	6	6.6.2	Alendronic acid 70 mg weekly annotated "not licensed for use in men but this is common practice"	Y	Y	8.4
18/10/2021	8	8.2.3	Ofatumumab assigned RED RAG status	Y	Y	11.3
18/10/2021	11	11.2	Link to MHRA DSU on chloramphenicol eye drops for children younger than 2 added	n/a	Y	4.11
18/10/2021	13	13.4	MHRA DSU link added: Topical corticosteroids: information on the risk of topical steroid withdrawal reactions	n/a	Y	5.2
18/10/2021	13	13..6.1, 13.6.2	Link added to NICE NG198: Acne vulgaris: management	n/a	Y	5.2
18/10/2021	13	13.5.1, 13.6.2	MHRA DSU link added: oral retinoids, temporary monitoring advice during COVID-19	Y	Y	5.2

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
18/10/2021	DNP		Deoxycholic acid (Belkya®) for treatment of moderate to severe convexity or fullness associated with submental fat ("double-chin") in adults assigned DNP status (criterion 1)	Y	n/a	n/a
15/10/2021	10	10.1.3	Guselkumab added to formulary with RED RAG status	n/a	Y	6.4
15/10/2021	RAG		Ravulizumab added to RAG list as a RED drug in line with TA698	Y	n/a	n/a
15/10/2021	RAG		Ravulizumab added to RAG list as a RED drug in line with TA710	Y	n/a	n/a
15/10/2021	RAG		Link to Indigo Gender Service shared care protocol added to leuprorelin, triptorelin, goserelin entries	Y	n/a	n/a
28/09/2021	RAG		Velafaxine: wording updated to clarify that RAG status of green (specialist initiation) only applies for total daily doses of 300 mg or more, and that lower doses are suitable for initiation in primary care.	Y	n/a	n/a
27/09/2021	2	Notes	Text on page 2 corrected to read "NB hypokalaemia can predispose to digitalis toxicity. Caution when used with diuretics."	n/a	Y	6.4
27/09/2021	5	5.1.4	Tobramycin for CF in adults: Amber line deleted, as all patients now repatriated.	Y	Y	6.1
27/09/2021	6	6.1.2.3	Temp RAG status for oral semaglutide updated to permanent decision (green) with grey status removed.	Y	Y	8.3
24/09/2021	RAG		Housekeeping: commissioners harmonised and entries edited for clarity. No changes to any RAG status.	Y	n/a	n/a
24/08/2021	3	3.2	Removed incorrect statement regarding Fostair NEXThaler: "Unlike the pressurised metered dose inhaler Fostair NEXThaler® is not licensed for the management of COPD, or for maintenance and reliever therapy (MART) in adults with asthma."	n/a	Y	6.4
12/08/2021	3	3.4.2	Omalizumab for chronic rhinosinusitis with nasal polyps added to DNP list, in line with NICE TA678	Y	Y	6.3
12/08/2021	9	9.1.4	Temp RAG status for avatrombopag made final (red)	Y	Y	5.2
12/08/2021	9	9.2.1.1	Temp RAG status for patiromer made final (red)	Y	Y	5.2
12/08/2021	10	10.1.3	Temp RAG status for upadacitinib made final (red)	Y	Y	6.3
12/08/2021	10	10.1.3	Temp RAG status for filgotinib made final (red)	Y	Y	6.3
12/08/2021	11	11.8.2.3	Temp RAG status for brolocizuab made final (red)	Y	Y	4.10
12/08/2021	13	13.5.3	Baricitinib assigned RED RAG status	Y	Y	5.1
12/08/2021	RAG		Anakinra added to RAG list as RED, with link to TA685	Y	n/a	n/a
05/08/2021	2	2.5.5.1	Temp RAG status for dapagliflozin in heart failure made final (green specialist advice)	Y	Y	6.3
05/08/2021	2	2.8.1	Temp RAG status for fondaparinux in ACS made final (red)	Y	Y	6.3
05/08/2021	4	4.5.1	Temp RAG status for liraglutide in obesity made final (red)	Y	Y	8.3
05/08/2021	4	4.7.4.2	Erenumab assigned RAG status: Red	Y	Y	8.3
05/08/2021	4	4.7.4.2	Temp RAG status for galcanezumab for migraine made final (red)	Y	Y	8.3
05/08/2021	4	4.7.4.2	Link to MHRA DSU on antiepileptic drugs in pregnancy added to topiramate for migraine	n/a	Y	8.3
05/08/2021	6	6.1.1.1	Lyumjev (insulin lispro) added to formulary as GREEN (following specialist advice) and GREY (criterion 2)	Y	Y	8.2
05/08/2021	6	6.6.2	Alendronic acid 70 mg weekly assigned GREEN RAG status	Y	Y	8.2
05/08/2021	6	6.6.2	Risedronate 35 mg weekly assigned GREEN RAG status	Y	Y	8.2
05/08/2021	6	6.6.2	Ibandronate tablets assigned GREEN RAG status	Y	Y	8.2
05/08/2021	6	6.6.2	Ibandronate 3mg/3ml injection for osteoporosis assigned RED RAG status	Y	Y	8.2
05/08/2021	8	8.3.4.2	Formatting improved. Links to shared care protocols added.	n/a	Y	8.2
08/07/2021	6	6.1.2.3	Wording for SGLT2 inhibitors updated to remove specific recommendations on which drugs have cardiovascular or renal outcome data; out of date. Awaiting update of NICE guidelines.	n/a	Y	8.2
21/05/2021	3	3.2	Added reference to chapter 2 for choices in heart failure.	n/a	Y	6.2
21/05/2021	3	3.1.3	Links for DHSC budesonide COVID-19 position statement added	n/a	Y	6.2
21/05/2021	3	3.1.3	Phyllocontin Continus and Forte Continus discontinued; removed from formulary and link added to DHSC supply alert	n/a	Y	6.2

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
21/05/2021	6	6.2.1	Link to MHRA DSU on switching between levothyroxine products added	n/a	Y	8.1
21/05/2021	6		Cost charts updated to latest versions (April 2021); insulin pens & cartridges, needles	n/a	Y	8.1
21/05/2021	8	8.2.3	Ofatumumab TA699 added to formulary, RAG status pending	n/a	Y	11.1
21/05/2021	10	10.1.3	Black triangles deleted: apremilast, ixekizumab. Black triangle added: belimumab	n/a	Y	6.2
21/05/2021	10	10.1.3	Added link to NG191 (managing COVID-19) to formulary	n/a	Y	6.2
21/05/2021	10	10.1.3	Added link to tofacitinib healthcare professional letter to formulary	n/a	Y	6.2
21/05/2021	13	13.5.3	Baricitinib TA684 added to formulary, RAG status pending	n/a	Y	5.0
21/05/2021	13	13.8.1	Link to superceded guidance on actinic keratoses deleted, GM primary care AK pathway added	n/a	Y	5.0
21/05/2021	13		Apremilast moved to sit alongside other cytokine modulators	n/a	Y	5.0
20/05/2021	2	2.12	Bempedoic acid TA694 added to formulary, RAG status pending	n/a	Y	6.2
20/05/2021	2	2.8.2	Links to NG196 (atrial fibrillation) added to formulary	n/a	Y	6.2
20/05/2021	2	2.8.2	Andexanet alfa TA697 added to formulary, RAG status pending	n/a	Y	6.2
20/05/2021	4	4.7.3	Added links to NG193 (chronic pain in over 16s) against relevant drugs	n/a	Y	8.2
20/05/2021	4	4.7.4.2	Erenumab TA682 added to formulary, RAG status pending	n/a	Y	8.2
19/05/2021	1	1.6.4 & 1.6.5	Link to MHRA DSU on mixing PEG laxatives & starch thickeners added	n/a	Y	1.2
19/05/2021	1	1.6.6	Note on appropriate naldemedine use added, to match RAG list	n/a	Y	6.2
19/05/2021	3	3.4.2	Temp DNP status for dupilumab (nasal polyyps) made final	Y	Y	6.2
19/05/2021	4	4.7.4.2	Temp RAG status for fremanezumab made final (red)	Y	Y	8.2
19/05/2021	6	6.1.2.3	Temp RAG status for dapagliflozin in T1DM made final (red)	Y	Y	8.1
19/05/2021	6	6.5.1	Temp RAG status for adult growth hormone made final (Green specialist initiation)	Y	Y	8.1
19/05/2021	RAG		To improve clarity & match formulary, Sportvis brand removed from DNP entry for synovial fluid injections	Y	n/a	n/a
07/04/2021	1	1.6.7	Linaclotide entry update to green (specialist initiation), in line with RAG list.	n/a	Y	6.1
05/03/2021	2	2.5	Dapagliflozin for heart failure added with link to NICE TA679, with temporary RAG status: Green (specialist advice)	Y	Y	6.1
05/03/2021	3	3.4.2	Link to TA431 (mepolizumab) deleted and replaced with updated link (TA671)	Y	Y	6.1
05/03/2021	10	10.1.3	Filgotinib added with link to TA676, with temporary RAG status: Red	Y	Y	6.1
05/03/2021	10	10.1.3	Baricitinib added to RAG list, reflecting formulary status	Y	n/a	n/a
05/03/2021	11	11.8.2.3	Brolucizumab added with link to TA672, with temporary RAG status: RED	Y	Y	5.0
19/02/2021	4	4.7.3 & 4.8.1	Link to MHRA DSU added to formulary - risk of respiratory depression with pregabalin	n/a	Y	8.1
19/02/2021	Paed RAG		Link to MHRA DSU added to paediatric RAG list - risk of adrenal insufficiency when switching from hydrocortisone tablet formulations to granules	Y	n/a	n/a
10/02/2021	9	9.1.4	Avatrombopag assigned temporary RAG status: RED	Y	Y	5.1
28/01/2021	4	4.3.3 & 4.3.4	Link to MHRA DSU on postpartum bleeding risk with SSRI/SNRI added.	n/a	Y	8.0
28/01/2021	4	4.3.4	Vortioxetine added to grey list and RAG status updated to GREEN specialist advice	Y	Y	8.0
28/01/2021	4	4.8.1	Link to MHRA DSU on antiepileptic drugs in pregnancy added	n/a	Y	8.0
28/01/2021	4	4.9.1	Safinamide RAG status updated to GREEN specialist advice	Y	n/a	n/a
28/01/2021	5	5.1.4	Link to MHRA DSU on aminoglycosides and deafness added.	n/a	Y	6.0
28/01/2021	6	6.1.1.2 & 6.1.1.3	Cost charts for insulin needles & insulins updated to most recent available (Oct 2020)	n/a	Y	8.0
28/01/2021	6	6.1.2.3	Oral semaglutide (Rybelsus) added as grey and GREEN (temporary status)	Y	Y	8.0

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
28/01/2021	6	6.1.2.3	Dapagliflozin in T1DM updated to RED (temporary RAG status). Wording updated to make clearer that this status applies only in T1DM, not T2DM.	Y	Y	8.0
28/01/2021	6	6.1.2.3	Ertugliflozin added to list of SGLT2 inhibitors with evidence of CV benefit	n/a	Y	8.0
28/01/2021	6	6.5.1	Somatropin for primary and secondary hypopituitarism assigned temporary RAG status: GREEN specialist initiation	Y	Y	8.0
28/01/2021	8	8.2.4	Links to MHRA DSUs on liver injury with fingolimod & PML with dimethyl fumarate added.	n/a	Y	11.0
28/01/2021	8	8.3.4.1	Anastrozole, exemestane, letrozole, tamoxifen assigned RAG status: GREEN specialist advice	Y	Y	11.0
28/01/2021	9	9.1.4	Avatrombopag added to formulary with link to TA626. RAG status pending	n/a	Y	5.0
28/01/2021	9	9.2.1.1	Sodium zirconium cyclosilicate added to formulary with link to TA	n/a	Y	5.0
28/01/2021	9	9.2.1.1	Patiromer added to formulary with link to TA and temporary RAG status: RED	Y	Y	5.0
28/01/2021	10	10.1.3	Upadacitinib assigned temporary RAG status: RED	Y	Y	6.0
27/01/2021	1	1.5.1	Mesalazine RAG status updated to GREEN specialist advice	Y	Y	6.0
27/01/2021	1	1.5.2	Budesonide RAG status updated to GREEN specialist advice	Y	Y	6.0
27/01/2021	1	1.5.2	Prednisolone rectal formulations RAG status updated to GREEN specialist advice	Y	Y	6.0
27/01/2021	1	1.6.6	Naldemedine given temporary RAG status: GREEN (specialist initiation)	Y	Y	6.0
27/01/2021	2	2.8.1	Fondaparinux added to formulary as per NICE NG185 for people with unstable angina or NSTEMI . Temporary RAG status: RED		Y	6.0
27/01/2021	2	2.8.1	RAG status for LMWH updated to accurately reflect RAG list	n/a	Y	6.0
27/01/2021	3	3.4.2	Dupilumab for chronic rhinosinusitis with nasal polyps added to DNP list, in line with NICE TA648. Temporary status	Y	Y	6.0
27/01/2021	4	4.10.3	Buprenorphine oral lyophilisate for opioid dependence added to formulary with temp RAG status of OTHER (in line with S/L buprenorphine). Temporary status	Y	Y	8.0
27/01/2021	4	4.5.1	Liraglutide for overweight and obesity assigned temporary RAG status: RED	Y	Y	8.0
27/01/2021	4	4.7.4.2	Fremanezumab & galcanezumab assigned temporary RAG status: RED	Y	Y	8.0
21/12/2020	1	1.3.3	Sucralfate oral suspension added to formulary as green specialist initiation	Y	Y	5.12
21/12/2020	1	1.5.3	Link to TA633 (ustekinumab for UC) added	n/a	Y	5.12
21/12/2020	1	1.6.6	Naldemedine added, with link to TA651	n/a	Y	5.12
21/12/2020	2	various	Added links to NG182 (acute coronary syndromes) and deleted superseded links (CG94, 167, 172)	n/a	Y	5.13
21/12/2020	3		Links to MHRA Drug Safety Update added	n/a	Y	5.12
21/12/2020	4	4.2	Link to NG181 (rehab for complex psychoses) added to formulary	n/a	Y	7.5
21/12/2020	4	4.5.1	Liraglutide removed from DNP list. Link to TA664 added to chapter 4.	Y	Y	7.5
21/12/2020	4	4.7.4.2	Fremanezumab & galcanezumab added, with link to TA631 & TA659	n/a	Y	7.5
21/12/2020	6	6.1.2.3	Dulaglutide added to list of GLP-1s with CV benefit, and updated to include all strengths available	n/a	Y	7.23
21/12/2020	8	8.2.4	Siponimod added, with link to TA656	n/a	Y	10.10
21/12/2020	9		Links to MHRA Drug Safety Update added	n/a	Y	4.9
21/12/2020	10	10.1.3	Upadacitinib added, with link to TA665	n/a	Y	5.9
21/12/2020	13		Links to MHRA Drug Safety Update added	n/a	Y	4.18
18/12/2020	1		Links to MHRA Drug Safety Update added	n/a	Y	5.12
18/12/2020	2		Links to MHRA Drug Safety Update added	n/a	Y	5.13
18/12/2020	6		Links to MHRA Drug Safety Update added	n/a	Y	7.23
18/12/2020	10		Links to MHRA Drug Safety Update added	n/a	Y	5.9
17/12/2020	4		Links to MHRA Drug Safety Update added	n/a	Y	7.5
17/12/2020	10	10.2.2	DNP status for Sativex removed	Y	Y	5.9
17/12/2020	RAG		Sodium zirconium cyclosilicate line updated to correct hypokalaemia to hyperkalaemia	Y	n/a	n/a